Gould TD

Departments of Psychiatry, Pharmacology-Physiology and Drug Discovery, and Neurobiology, University of Maryland School of Medicine, Baltimore, USA.

10 papers · ORCID

ArticleKetamine

Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology.

Gould TD, Mathew SJ, Fava M +1

Europe PMC2026
ArticleKetamine

Intermittent Ketamine and Neuromodulation Treatment Evoke Synergistic Antidepressant-Relevant Action.

Brown KA, Gould TD

Europe PMC2026
ArticlePsilocybin

Synaptic priming: A framework for pharmacotherapy in depression.

Brown KA, Ajibola MI, Medeiros GC +1

Europe PMC2025
ArticleKetamine

Personalized use of ketamine and esketamine for treatment-resistant depression.

Medeiros GC, Demo I, Goes FS +2

Europe PMC2024
ArticleKetamine

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.

Raja SM, Guptill JT, Mack M +38

Europe PMC2024
ArticleKetamine

Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions.

Loan Nguyen TM, Guilloux JP, Defaix C +13

Europe PMC2024
ArticleKetamine

Entactogen Effects of Ketamine: A Reverse-Translational Study.

Hess EM, Greenstein DK, Hutchinson OL +2

Europe PMC2024
ArticleKetamine

Targeting metaplasticity mechanisms to promote sustained antidepressant actions.

Brown KA, Gould TD

Europe PMC2024
ArticleKetamine

Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.

Medeiros GC, Matheson M, Demo I +8

Europe PMC2023
ArticlePsychedelics

Possible psychedelic therapeutic mechanism.

Hess EM, Gould TD

Europe PMC2023